Private Equity

Updated:

ScienceVest

ScienceVest (YC F3) is a seed stage fund for hard-tech and life science companies supporting founders with seed stage capital for their journey of changing the...

ScienceVest logo

ScienceVest

ScienceVest (YC F3) is a seed stage fund for hard-tech and life science companies supporting founders with seed stage capital for their journey of changing the world through breakthrough science.

General information

Firm type

Private Equity

Year founded

2016

AUM

Undisclosed

Location

Region

North America

Country

United States

City

San Francisco

Corporate office

San Francisco, CA, United States

Sector focus

Digital HealthEnterprise Software

Frequently asked questions

Who runs investment decisions at ScienceVest?

ScienceVest’s website identifies Javier Loya and Ramphis M. Castro as the principals, listing their email addresses as primary contact points. No other named team members, board structures, or investment committees are disclosed. As a result, the full decision-making process remains opaque to external allocators.

What investment stages does ScienceVest typically target?

ScienceVest focuses on early-stage seed rounds, per its Altss research classification and portfolio composition. Its publicly highlighted companies — such as Avro Lifescience (a drug-delivery patch startup) and GreenSight (drone automation) — align with pre-revenue or early-commercialization science-based ventures.

Does ScienceVest participate in fund commitments or only direct deals?

The public materials reference only direct investments. ScienceVest does not list any fund-of-funds activity, co-investment vehicles, or SPV programs. The roughly 125 investments the firm claims appear to be direct company stakes.

Which sectors does ScienceVest explicitly avoid?

ScienceVest's portfolio emphasizes life sciences and industrial technology, with no evidence of consumer internet, financial services, or media investments. The firm's name and portfolio suggest an avoidance of sectors distant from scientific R&D, but no explicit exclusion list is published.

How does ScienceVest source proprietary deal flow?

With a minimal public brand and no LinkedIn presence, ScienceVest likely relies on the scientific networks of Loya and Castro. The portfolio includes university spinout-style ventures — Avro Lifescience and Calyx (formerly BioInspira) — pointing to academic lab and research institution origination rather than auctioned venture rounds.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on private equity firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More San Francisco Private Equity profiles